Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03031730 · ClinicalTrials.gov registry record · Phase 1
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT03031730: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT03031730 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 35 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03031730, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of MDM2 Inhibitor KRT-232 when given together with carfilzomib, lenalidomide, and dexamethasone in treating patient with multiple myeloma that has come back (relapsed) or has not responded to previous treatment (refractory). KRT-232 (AMG 232) may stop the growth of cancer cells by blocking a protein called MDM2 that is needed for cell growth. Lenalidomide help shrink or slow the growth of multiple myeloma. Drugs used in chemotherapy, such as carfilzomib and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving MDM2 Inhibitor KRT-232, lenalidomide, carfilzomib, and dexamethasone together may work better in treating patients with multiple myeloma.
Interventions
- PROCEDURE Biospecimen Collection
- DRUG Dexamethasone
- PROCEDURE Bone Marrow Aspiration and Biopsy
- DRUG Carfilzomib
- DRUG Dexamethasone Sodium Phosphate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2018-06-14 |
| Est. Completion | 2024-07-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03031730
The ClinicalTrials.gov registry entry for NCT03031730 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT03031730 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03031730 about?
NCT03031730 is a clinical study titled "Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma". This phase I trial studies the side effects and best dose of MDM2 Inhibitor KRT-232 when given together with carfilzomib, lenalidomide, and dexamethasone in treating patient with multiple myeloma that has come back (relapsed) or has not responded to previous treatment (refractory). KRT-232 (AMG 232)...
What is the current status of trial NCT03031730?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2018-06-14. Estimated completion is 2024-07-24.
What interventions are being tested in trial NCT03031730?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Dexamethasone (DRUG), Bone Marrow Aspiration and Biopsy (PROCEDURE), Carfilzomib (DRUG), Dexamethasone Sodium Phosphate (DRUG).
Who is sponsoring clinical trial NCT03031730?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.